COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD

Source   Share   Tweet
See all 143 studies
Karatza et al., Xenobiotica (Peer Reviewed) (not included in the study count)
Optimization of hydroxych loroquine dosing scheme based on COVID-19 patients’ characteristics: a review of the literature and simulations
Analysis of HC Q dosing, suggesting that high initial doses followed by low and sparse doses may offer significant benefits to patients by decreasing the viral load without reaching levels considered to produce adverse effects.
For instance, the dosing scheme proposed for a 70kg adult with moderate COVID-19 symptoms would be 600mg upon diagnosis, 400mg after 12h, 300mg after 24h, 200mg after 36h, followed by 200mg BID for 4 days, followed by 200mg OD for 5 days.
Suboptimal dosing regimens that do not fully account for the long half-life of HC Q or the patient characteristics are likely contribute to either limited efficacy where therapeutic levels take too long to reach, or significant adverse effects due to excessive dosage.
Source   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.